bluebird bio, Inc. - Common Stock (NQ:BLUE)

4.970 UNCHANGED

Last Price Updated: 4:00 PM EDT, May 30, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about bluebird bio, Inc. - Common Stock

< Previous 1 2

...

16 17 18 19 20 21 22 23 Next >

The Daily Biotech Pulse: MacroGenics' Clinical Trial Disappointment, Sanofi to Buy Kadmon, Alector Loses 2 Key Executives, ADMA's FDA Nod ↗

September 08, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 7) Adial Pharmaceuticals, Inc...

Via Benzinga

bluebird bio Secures $75 Million in Private Placement Equity Financing

September 08, 2021

From bluebird bio, Inc.

Via Business Wire

SVB Leerink Says 'We Were Wrong,' Slashes Bluebird Bio Price Target ↗

August 09, 2021

After the

Via Benzinga

The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight ↗

August 08, 2021

Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in,...

Via Benzinga

bluebird bio Announces Key Management and Board Appointments and Upcoming Investor Events

September 07, 2021

From bluebird bio, Inc.

Via Business Wire

The Latest Barron's Picks And Pans Include General Electric, Netflix, Reddit And More ↗

September 04, 2021

This weekend's Barron's reveals what market strategists recommend for a stock market that likely will struggle this fall. Other featured articles discuss biotech stocks...

Via Benzinga

3 Beaten-Down Biotech Stocks to Buy Right Now ↗

August 18, 2021

These biotech stocks might be down, but they're not out.

Via The Motley Fool

BLUEBIRD BIO INVESTIGATION INITIATED By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of bluebird bio, Inc. - BLUE

August 13, 2021

From Kahn Swick & Foti, LLC

Via Business Wire

The Daily Biotech Pulse: J&J Announces CEO Transition, FibroGen's Roxadustat Approved In Europe, GeoVax, Sorrento Announce COVID-19 Vaccine Data ↗

August 20, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 19) Alkermes plc (NASDAQ: ALKS...

Via Benzinga

The Daily Biotech Pulse: FDA Rejects FibroGen's Anemia Drug, Crinetics Gains On Positive Readout, BioCryst Withdraws Public Offering ↗

August 11, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 10) Alnylam Pharmaceuticals,...

Via Benzinga

Stocks That Hit 52-Week Lows On Tuesday ↗

August 10, 2021

Before 10 a.m. ET on Tuesday, 60 companies set new 52-week lows. Key Facts: PACCAR (NASDAQ:PCAR) was the biggest company by market cap to set a new 52-week low....

Via Benzinga

Why Bluebird Bio's Stock Is Trading Lower Today ↗

August 09, 2021

Bluebird Bio Inc (NASDAQ: BLUE) is trading lower Monday after the company reported worse-than-expected second-quarter financial results and announced that the FDA placed...

Via Benzinga

The Daily Biotech Pulse: Arcturus Soars On COVID-19 Vaccine Updates, Merck's Keytruda On Track For More Label Expansions, Eliem Debuts ↗

August 10, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 9) Adagio Therapeutics, Inc. (...

Via Benzinga

68 Biggest Movers From Yesterday ↗

August 10, 2021

Gainers Golden Nugget Online Gaming, Inc. (NASDAQ: GNOG) shares climbed 50.8% to close at $18.50 on Monday after the company and DraftKings announced they entered into a...

Via Benzinga

Bluebird Stock Crashes To 7-Year Low After FDA Pauses Gene Therapy Test ↗

August 09, 2021

Bluebird Bio said Monday the FDA paused one of its gene therapy studies due to safety concerns, and BLUE stock collapsed.

Via Investor's Business Daily

Why Bluebird Bio Stock Is Crashing Today ↗

August 09, 2021

The drugmaker had a double whammy of bad news.

Via The Motley Fool

12 Health Care Stocks Moving In Monday's Intraday Session ↗

August 09, 2021

Gainers SCWorx (NASDAQ:WORX) shares moved upwards by 33.66% to $4.3 during Monday's regular session. As of 12:30 EST, this security is trading at a volume of 87.6...

Via Benzinga

Bluebird Bio's Shares Drop To 52-Week Low After Another Gene Therapy Trial Placed On FDA Hold ↗

August 09, 2021

Shares for Bluebird Bio Inc (NASDAQ: BLUE) is hovering at a 52-week low after the FDA placed a clinical hold on clinical studies of elivaldogene autotemcel (...

Via Benzinga

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

August 09, 2021

Gainers Windtree Therapeutics (NASDAQ:WINT) stock rose 30.38% to $2.36 during Monday's pre-market session. The company's market cap stands at $61.9 million. The...

Via Benzinga

Recap: bluebird bio Q2 Earnings ↗

August 09, 2021

Shares of bluebird bio (NASDAQ:BLUE) moved higher by 0.9% in pre-market trading after the company reported Q2 results. Quarterly Results Earnings per share were down 852.78...

Via Benzinga

Stocks That Hit 52-Week Lows On Monday ↗

August 09, 2021

Before 10 a.m. ET Monday, 63 stocks made new 52-week lows. Intriguing Points: The largest company by market cap to set a new 52-week low was PACCAR (NASDAQ:PCAR)....

Via Benzinga

bluebird bio Reports Second Quarter Financial Results and Provides Operational Update

August 09, 2021

From bluebird bio, Inc.

Via Business Wire

bluebird bio Announces Q2 Earnings Call and Upcoming Investor Events

August 05, 2021

From bluebird bio, Inc.

Via Business Wire

bluebird bio, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 04, 2021

From bluebird bio, Inc.

Via Business Wire

Is This Small-Cap Biotech a Buy After Its Second Approved Gene Therapy? ↗

August 03, 2021

After receiving yet another treatment approval from regulators, Bluebird Bio looks like a bargain.

Via The Motley Fool

Bluebird Bio and Resilience Announce Strategic Alliance to Develop Next Generation Cell Therapies

July 28, 2021

From bluebird bio, Inc. and Resilience

Via Business Wire

The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs ↗

August 01, 2021

Biotech stocks showed a lack of direction in the week ending July 30 amid earnings releases from big pharma companies. Most pharma majors reported strong quarterly results....

Via Benzinga

bluebird bio Receives EC Approval for SKYSONA™ (elivaldogene autotemcel, Lenti-D™) Gene Therapy for Patients Less Than 18 Years of Age With Early Cerebral Adrenoleukodystrophy (CALD) Without Matched Sibling Donor

July 21, 2021

From bluebird bio, Inc.

Via Business Wire

Should Investors Hold Out Hope for bluebird bio and Merck Spinoff Organon? ↗

July 10, 2021

Neither healthcare stock has performed well so far this year.

Via The Motley Fool

Bluebird Bio To Resume Zynteglo Gene Therapy Marketing In Europe After Positive Recommendation From PRAC ↗

July 09, 2021

European Medicines Agency's (EMA) Pharmacovigilance Risk Assessment Committee (PRAC) has concluded that the benefit-risk of Bluebird Bio Inc's (NASDAQ: BLUE)...

Via Benzinga

< Previous 1 2

...

16 17 18 19 20 21 22 23 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.